Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Ishara Investments LP
Form 13F · Q2 2026

Ishara Investments LP

CIK 2111609Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$136M
Reported book value
41
Positions
3
Quarters on record
Top 50
Positions

Ishara Investments LP — holdings

Top 41 positions of 41, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1ACAD Acadia Pharmaceuticals Inc410,000+233.3%$10M7.6%
2XERS Xeris Biopharma Holdings Inc1.2M+20.0%$10M7.2%
3BMRN Biomarin Pharmaceutical Inc143,500+75.0%$8M6.0%
4PRAX Praxis Precision Medicines I22,550+0.0%$8M5.5%
5RARE Ultragenyx Pharmaceutical In205,000+17.6%$7M5.0%
6AGIO Agios Pharmaceuticals Inc164,000—$6M4.5%
7INSM Insmed Inc51,250—$5M4.0%
8CRINETICS PHARMACEUTICALS IN Crinetics Pharmaceuticals In143,500—$5M3.9%
9ZNTL Zentalis Pharmaceuticals Inc1.0M−16.7%$5M3.7%
10PCVX Vaxcyte Inc82,000+42.9%$5M3.5%
11ANNX Annexon Inc820,000+370.6%$5M3.4%
12TVTX Travere Therapeutics Inc82,000−25.9%$5M3.4%
13TNXP Tonix Pharmaceuticals Hldg C338,250—$4M3.2%
14BBIO Bridgebio Pharma Inc57,400—$4M3.1%
15AXSM Axsome Therapeutics Inc.16,400−60.0%$4M2.9%
16CTNM Contineum Therapeutics Inc205,000+44.4%$3M2.5%
17LXRX Lexicon Pharmaceuticals Inc1.3M+40.9%$3M2.2%
18KURA Kura Oncology Inc276,750—$3M2.2%
19DBVT Dbv Technologies S A184,500+80.0%$3M2.2%
20GMAB Genmab A/S102,500+25.0%$3M2.1%
21CYTK Cytokinetics Inc32,800—$3M2.1%
22MLYS Mineralys Therapeutics Inc102,500+25.0%$3M2.0%
23SLN Silence Therapeutics Plc55,350−60.6%$2M1.8%
24NUVB Nuvation Bio Inc369,000—$2M1.5%
25WVE Wave Life Sciences Ltd328,000—$2M1.4%
26NKTR Nektar Therapeutics26,650—$2M1.4%
27SRRK Scholar Rock Hldg Corp30,750−46.4%$2M1.2%
28ELVN Enliven Therapeutics Inc32,800—$2M1.2%
29ALNY Alnylam Pharmaceuticals Inc5,125+0.0%$2M1.1%
30BEAM Beam Therapeutics Inc41,000−28.6%$1M1.0%
31SION Sionna Therapeutics Inc123,000+150.0%$1M1.0%
32ORIC Oric Pharmaceuticals Inc123,000+20.0%$1M1.0%
33NAMS Newamsterdam Pharma Company36,900+0.0%$1M0.9%
34VERTEX PHARMACEUTICALS INC Vertex Pharmaceuticals Inc2,460—$1M0.9%
35SPRY Ars Pharmaceuticals Inc143,490—$1M0.8%
36MNPR Monopar Therapeutics Inc12,300—$1M0.8%
37ERAS Erasca Inc41,000—$751,1200.6%
38VERA Vera Therapeutics Inc10,250−87.5%$439,8280.3%
39IMTX Immatics N.V30,750−80.0%$311,4980.2%
40MREO Mereo Biopharma Group Plc768,750—$244,2320.2%
41GOSS Gossamer Bio Inc820,000+0.0%$134,9720.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.